<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493204</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00141457</org_study_id>
    <nct_id>NCT03493204</nct_id>
  </id_info>
  <brief_title>Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial</brief_title>
  <official_title>Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of a home meal delivery program for
      patients with cirrhosis and ascites and to determine the effectiveness of a salt-restricted
      (2 gram sodium) meal delivery program in reducing the need for therapeutic paracenteses
      and/or all-cause re-admissions for these patients. Many patients with cirrhosis don't have
      enough nutrients in the body and are frail and these meals may help them maintain a good diet
      and lead to improved quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of therapeutic paracenteses</measure>
    <time_frame>From date of randomization until 12 weeks</time_frame>
    <description>Number of paracenteses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>Measured by Ascites Symptom Inventory (ASI-7). This is a 7 question scale that measures the subject's symptoms with a value from 0-4 (0=does not apply / 4=very strong applies). The higher the subject's score the worse the subject's symptoms. The mean change will be compared between groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of hospital-bed days in 12 weeks</measure>
    <time_frame>From date of randomization until 12 weeks</time_frame>
    <description>The number of days the participants were hospitalized after randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in diuretic dose</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>The dose amount changes the participant's medications that are considered diuretics</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in frailty measures</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>Change in the hand grip strength using a hand-held dynamometer. The device will be squeezed 3 times with their dominant hand and the force measured in kilograms. The best recorded value (highest force number) will be their value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in frailty measures</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>Change in time taken to walk 5 meters (walk speed measured in meters per second)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>Change in Visual Analog Scale. The subject selects how their health is today by marking an X on the scale from 0-100; 0= worst imaginable health state / 100= best imaginable health state</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Ascites</condition>
  <condition>Liver Diseases</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Home-delivered, salt restricted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meal description: salt-restricted (1500 mg to 2000 mg daily), &gt; 2100 kilocalorie, high protein (&gt;80 g daily) in addition to receiving standard pamphlet receipt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary Advice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care, advice on salt-restriction using standard pamphlet receipt</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meal delivery</intervention_name>
    <description>The food will be pre-packaged for storage and patient will prepare these meals at home</description>
    <arm_group_label>Home-delivered, salt restricted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard pamphlet with Dietary Advice</intervention_name>
    <description>Explains how to maintain a low-sodium diet</description>
    <arm_group_label>Dietary Advice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult 18 years or older of age

          -  Clinical diagnosis of cirrhosis with ascites. Diagnosis of cirrhosis will be based
             upon:

               1. liver biopsy, OR

               2. history of cirrhosis complication: ascites, variceal bleeding, hepatic
                  encephalopathy, OR

               3. 2 of the following 4 criteria: i. Ultrasound (US), computerized axial tomography
                  (CT) or Magnetic Resonance Imaging (MRI) imaging findings of cirrhosis (cirrhotic
                  appearing liver, splenomegaly, varices, ascites) ii. Fibroscan liver stiffness
                  score &gt;13 kPa iii. Laboratory testing: Aspartate Aminotransferase (AST)/platelet
                  ratio index (APRI) &gt;2.0 iv. CT, MRI or Esophagogastroduodenoscopy (EGD) showing
                  presence of esophageal varices

          -  3) At least one of the following: Any cause hospitalization within 90 days OR
             outpatient therapeutic paracentesis within 30 days

        Exclusion Criteria:

          -  Language barriers that cannot be surmounted with in-person interpreters

          -  Estimated life expectancy &lt; 3 months

          -  Pregnancy (self-reported)

          -  Unable or unwilling to provide consent

          -  History of liver transplant

          -  Planned discharge to nursing facility

          -  Anuria or serum creatinine &gt; 2.0 mg/dL

          -  Diabetes Mellitus

          -  Uncontrolled hepatic encephalopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Tapper</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Wong</last_name>
    <phone>734-232-0284</phone>
    <email>janejw@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Wong</last_name>
      <phone>734-232-0284</phone>
      <email>janejw@med.umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Elliot B. Tapper</investigator_full_name>
    <investigator_title>Assistant Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Ascites</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

